These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 16327838)

  • 1. Therapy Insight: pyoderma gangrenosum-old disease, new management.
    Campbell S; Cripps S; Jewell DP
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):587-94. PubMed ID: 16327838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
    Swale VJ; Saha M; Kapur N; Hoffbrand AV; Rustin MH
    Clin Exp Dermatol; 2005 Mar; 30(2):134-6. PubMed ID: 15725238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
    Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
    Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?
    Adişen E; Oztaş M; Gürer MA
    Dermatology; 2008; 216(2):163-5. PubMed ID: 18216480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of peristomal pyoderma gangrenosum.
    Kiran RP; O'Brien-Ermlich B; Achkar JP; Fazio VW; Delaney CP
    Dis Colon Rectum; 2005 Jul; 48(7):1397-403. PubMed ID: 15868233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
    Stichweh DS; Punaro M; Pascual V
    Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophilic dermatoses: a review of current treatment options.
    Cohen PR
    Am J Clin Dermatol; 2009; 10(5):301-12. PubMed ID: 19658442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory pyoderma gangrenosum treated with infliximab in an infant.
    Campos-Muñoz L; Conde-Taboada A; Aleo E; Toledano E; López-Bran E
    Clin Exp Dermatol; 2014 Apr; 39(3):336-9. PubMed ID: 24635074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
    Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
    Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of Pyoderma gangrenosum with potassium iodide.
    Asahina A; Minatani Y; Tada Y; Mitsui H; Tamaki K
    Acta Derm Venereol; 2006; 86(1):84-5. PubMed ID: 16586005
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pyoderma gangrenosum: case series].
    Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
    Clin Ter; 2007; 158(4):325-9. PubMed ID: 17953284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
    Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
    Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy.
    Bruzzese V
    J Clin Rheumatol; 2012 Dec; 18(8):413-5. PubMed ID: 23188209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum.
    Seishima M; Mizutani Y; Shibuya Y; Nagasawa C; Aoki T
    Ther Apher Dial; 2007 Jun; 11(3):177-82. PubMed ID: 17497998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients.
    Reichrath J; Bens G; Bonowitz A; Tilgen W
    J Am Acad Dermatol; 2005 Aug; 53(2):273-83. PubMed ID: 16021123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report.
    Baglieri F; Scuderi G
    Dermatol Ther; 2010; 23(5):541-3. PubMed ID: 20868408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid improvement of pyoderma gangrenosum after treatment with infliximab.
    Chan JL; Graves MS; Cockerell CJ; Pandya AG
    J Drugs Dermatol; 2010 Jun; 9(6):702-4. PubMed ID: 20645536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

  • 20. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
    Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
    Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.